hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
mitophagy The selective degradation of mitochondria by means of autophagy; i.e. the mitochondrion initiates its own degradation. Mitophagy is a regular process in healthy populations of cells by which defective or damaged mitochondria are recycled, preventing their accumulation. It may also occur in response to the changing metabolic needs of the cell, e.g. during certain developmental stages.
Moxonidine (INN) is an imidazoline receptor agonist antihypertensive drug licensed for the treatment of mild to moderate essential hypertension. It may have a role when thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or have failed to control blood pressure. In addition, it demonstrates favourable effects on parameters of the insulin resistance syndrome, apparently independent of blood pressure reduction. It is also a growth hormone releaser. It is manufactured by Solvay Pharmaceuticals (acquired by Abbott in 2009) under the brand name Physiotens and Moxon.
== As a drug target == Xenin promotes beta-cell survival and xenin has been evaluated in animal models of obesity and diabetes where it has demonstrated an antidiabetic potential. In humans, co-administration of xenin-25 and gastric inhibitory polypeptide (GIP) reduces postprandial glycemia by delaying gastric emptying.
Supratrochlear nerve and the supraorbital nerve from the ophthalmic division of the trigeminal nerve Greater occipital nerve (C2) posteriorly up to the vertex Lesser occipital nerve (C2) behind the ear Zygomaticotemporal nerve from the maxillary division of the trigeminal nerve supplying the hairless temple Auriculotemporal nerve from the mandibular division of the trigeminal nerve The innervation of scalp can be remembered using the mnemonic 'Z-GLASS' for Zygomaticotemporal nerve, Greater occipital nerve, Lesser occipital nerve, Auriculotemporal nerve, Supratrochlear nerve, and Supraorbital nerve. The motor innervation of the scalp, specifically, the occipitofrontalis muscle, is split into two main factions: the frontal belly or frontalis muscle is supplied by the temporal branch of facial nerve, while the occipital belly or occipitalis is supplied by the posterior auricular branch of facial nerve.
Sources: en.wikipedia.org
In early April, Sykes and Picot were appointed to act as the chief negotiators once more, this time on a month-long mission to the Middle East for further discussions with the Sherif of Mecca and other Arab leaders. On 3 April 1917, Sykes met with Lloyd George, Lord Curzon and Maurice Hankey to receive his instructions in this regard, namely to keep the French onside while "not prejudicing the Zionist movement and the possibility of its development under British auspices, [and not] enter into any political pledges to the Arabs, and particularly none in regard to Palestine". Before travelling to the Middle East, Picot, via Sykes, invited Nahum Sokolow to Paris to educate the French government on Zionism. Sykes, who had prepared the way in correspondence with Picot, arrived a few days after Sokolow; in the meantime, Sokolow had met Picot and other French officials, and convinced the French Foreign Office to accept for study a statement of Zionist aims "in regard to facilities of colonization, communal autonomy, rights of language and establishment of a Jewish chartered company." Sykes went on ahead to Italy and had meetings with the British ambassador and British Vatican representative to prepare the way for Sokolow once again. Sokolow was granted an audience with Pope Benedict XV on 6 May 1917. Sokolow's notes of the meeting – the only meeting records known to historians – stated that the Pope expressed general sympathy and support for the Zionist project.
Although WHO recommends artemisinin-based remedies for treating uncomplicated malaria, resistance to the drug can no longer be ignored. Also in the 1970s Chinese researcher Zhang TingDong and colleagues investigated the potential use of the traditionally used substance arsenic trioxide to treat acute promyelocytic leukemia (APL). Building on his work, research both in China and the West eventually led to the development of the drug Trisenox, which was approved for leukemia treatment by the FDA in 2000. Huperzine A, an extract from the herb, Huperzia serrata, is under preliminary research as a possible therapeutic for Alzheimer's disease, but poor methodological quality of the research restricts conclusions about its effectiveness. Ephedrine in its natural form, known as má huáng (麻黄) in TCM, has been documented in China since the Han dynasty (206 BCE – 220 CE) as an antiasthmatic and stimulant. In 1885, the chemical synthesis of ephedrine was first accomplished by Japanese organic chemist Nagai Nagayoshi based on his research on Japanese and Chinese traditional herbal medicines Pien tze huang was first documented in the Ming dynasty.
=== Viral-mediated delivery === The gene silencing effects of transfected, designed siRNA are generally transient, but this difficulty can be overcome through an RNAi approach. Delivering this siRNA from DNA templates can be done through several recombinant viral vectors based on retrovirus, adeno-associated virus, adenovirus, and lentivirus. As of primary research work in 2006, the latter virus was the most efficient for stable delivery of siRNA to target cells, as it could be used to transduce nondividing cells, as well as to directly target the nucleus. These specific viral vectors have been synthesized to effectively facilitate siRNA that is not viable for transfection into cells. In some cases synthetic viral vectors can integrate siRNA into the cell genome, which allows for stable expression of siRNA and long-term gene knockdown. This technique is advantageous because it is an in vivo method, and can be effective for difficult to transfect cells. However, problems arise because it can trigger antiviral responses in some cell types, leading to mutagenic and immunogenic effects. This method has been shown to have potential for use in gene silencing of the central nervous system genes, e.g., in the treatment of Huntington's disease.
Liposarcoma treatment usually consists of surgical resection, with chemotherapy considered depending on the aggressiveness of the sarcoma. Radiotherapy may also be used before or after surgical excision for liposarcoma. Pediatric rhabdomyosarcoma is usually treated with chemotherapy, surgery, and sometimes radiotherapy. Pediatric rhabdomyosarcoma patients have a 50–85% long term survival rate. Osteosarcoma is a cancer of the bone that is treated with surgical resection of as much of the cancer as possible, often along with chemotherapy. Radiotherapy is a second alternative to surgery, although not as successful. It was believed that higher doses of chemotherapy might improve survival. However, high doses of chemotherapy stop the production of blood cells in the bone marrow and can be harmful. Stem cells collected from people before high‐dose chemotherapy can be transplanted back to the person if the blood cell count gets too low; this is called autologous hematopoietic stem cell transplantation, or high dose therapy with stem cell rescue. Research to investigate if using high‐dose chemotherapy followed by autologous hematopoietic stem cell transplantation was more favourable than standard‐dose chemotherapy found only one RCT and this did not favour either of the two treatment arms with respect to overall survival. As a result, high dose chemotherapy with stem cell rescue is generally considered appropriate only in the research setting.
Starch is stored in granule form. Starch granules are composed of a crystalline structure of amylopectin and amylose. Amylopectin forms the structure of the starch granule, with branching and non branching A-chains, B-chains, and C-chains. Amylose fills in the gaps of the amylopectin structure. Under a microscope, starch granules look like concentric layers, referred to as “growth rings”. Starch granules also contain granule-bound starch synthase and amylopectin synthesizing enzymes. Notably, starch granules vary in size and morphology across plant tissues and species.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.